AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05677685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VISUPRIME
Description: twice daily
Study NCT05677685 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily
Study NCT04291170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QDASH
Description: completing the tasks on the QDASH: open jar, wash wall, carry shopping bag, wash back, cut food, hammer wood
Study NCT05061290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Porridge
Description: Maize porridge containing 54Fe as iron sulfate
Study NCT04291170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KOOSJR
Description: completing tasks on the KOOSJR: pivot, straighten, go up/down stairs, stand upright, rise from sitting, bend over
Study NCT05030285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The CBT intervention includes 6 sessions via video-conferencing that has been tailored for people living with cognitive impairment. The sessions incorporate the use of psychoeducation and relaxation videos to improve home-based practise for long-term outcomes.
Study NCT06043544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe
Description: Patients in the treatment group received two intra-articular injections with Hymovis® (24mg/3ml) a week apart from each other
Study NCT06043544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.
Study NCT05061290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference Porridge A
Description: Maize porridge counting 58Fe as iron sulfate with ascorbic acid
Study NCT06530472 — intervention group
Intervention type: OTHER
Intervention: Monitoring
Description: At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.
Study NCT05061290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Porridge B
Description: Maize porridge containing 57Fe and fortified with Moringa leaf powder as iron source
Study NCT05061290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Porridge C
Description: Maize porridge containing 57Fe and fortified with Boabab fruit powder as iron source
Study NCT05061290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Porridge D
Description: Maize porridge containing 54Fe and fortified with Moringa leaf and Baobab fruit powder as iron source
Study NCT06006364 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The scales and forms used are respectively:~1. Demographic Information Form~2. Nomophobia Scale~3. Cornell Musculoskeletal Disorder Questionnaire~4. Smart phone Addiction Scale~5. Pittsburgh Sleep Quality Index~6. International Physical Activity Survey~7. McGill Melzack Pain Questionnaire
Study NCT05339776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand Lateralization Test
Description: Before hand lateralization test, participants will be evaluated. Both groups (Amputees and Control) will complete hand lateralization test for at least 10 days. The test will be sent each day on an online system. Participants' performances will be recorded via online system. After hand lateralization test, participants will be evaluated.
Study NCT06101225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MindRegulation Intervention
Description: The intervention is developed in class for 15 minutes before learning activities, three times per week, for five months - 57 sessions. Six different scripts with socioemotional learning content (based on CASEL framework) for each of the three themes will be applied.
Study NCT06101225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: The relaxation condition will be developed in the same way as in RegularMente intervention, but without the guided imagery with SEL component. Relaxation exercises applied in class 15 minutes before learning activities, three times per week, for five months - in a total of 57 sessions.
Study NCT06101225 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List Control Group
Description: No Intervention.
Study NCT06148844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive robot group
Description: Intervention group will receive one day pre-operative preparation intervention applied by researcher. Preparation will be 30-40 minutes long
Study NCT05918471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very Low Energy Diet with Liquid Supplementation
Description: The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows:~1. Consume 4 Optifast 900 packets each day~2. Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks.~3. Mix 1 sachet with at least 300 mL (1 1⁄4 cups) of cold water. Shake well or blend in a blender.
Study NCT05690867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Starting with volume controlled ventilation and changing the ventilation mode every 20 minutes
Description: group 1 starts with volume controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to pressure controlled ventilation after letting washout we take three consecutive measurements at pressure controlled ventilation and we will repeat this protocol during surgery
Study NCT05690867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Starting with pressure controlled ventilation and changing the ventilation mode every 20 minutes
Description: group 2 starts with pressure controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to volume controlled ventilation after letting washout we take three consecutive measurements at volume controlled ventilation and we will repeat this protocol during surgery
Study NCT05896267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo INVSENSOR00061
Description: Masimo INVSENSOR00061 will be used to measure noninvasive SpO2 (Oxygen Saturation ) in blood .
Study NCT06105905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy futures (Futuros Saludables)
Description: The developed intervention will be delivered in a workshop format by facilitators, over 8 sessions for teens and 2 sessions for parent/guardian(s). Feedback on delivery mode (virtual, in-person, or hybrid) during the co-development sessions. If in-person/hybrid is suggested, feedback will be elicited about preferred location (e.g., a local community center, sports club, etc.). Participants will complete sessions, in either Spanish or English depending on participants' preference, using video conference tools. After the delivery of the intervention, facilitators will take field notes and complete a debriefing questionnaire to assess practicality and fidelity. Parent/guardians will complete a 5 minute pre- and post- intervention survey. Teens will complete a 15 minute survey pre-intervention, immediately post-intervention, three-month, six-month, and twelve-month post-intervention. Surveys will assess acceptability and risk behaviors.
Study NCT06307925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC010
Description: HC010 Q2W/28d intravenous infusion
Study NCT06595030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Lighting Intervention
Description: The TLI will allow researchers to use a light source that will control how the circadian system is stimulated and provide the participants with options as to how the light treatment will be delivered.
Study NCT06595030 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Lighting Intervention
Description: The TLI will allow researchers to use a light source that will not stimulate the circadian system and provide the participants with options as to how the light treatment will be delivered.
Study NCT05984420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LimpiAD 2,5% plus cream
Description: A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
Study NCT05984420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Vehicle of LimpiAD 2.5 % plus cream which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus but without the HAc-40 component.
Study NCT05984420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emollient
Description: Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
Study NCT05646524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
Study NCT06044701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hologram Distraction Technique
Description: Hologram fan application during blood collection process
Study NCT06044701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bubble Machine Distraction Technique
Description: Bubble machine application during blood collection
Study NCT00710216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 100 mg/day
Study NCT00710216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600 mg/day
Study NCT05318742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: Endolaser photocoagulation during PPV
Study NCT02422368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone + ASTED
Description: ASTED tablet: Twice daily for 6 months~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company....) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups.
Study NCT02422368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone +Placebo
Description: Placebo: twice daily~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company....) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups.
Study NCT05213728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN
Description: Norovirus GI.1 Norwalk VP1 Vaccine (VXA-G1.1-NN) E1/E3-Deleted Replication-Defective Recombinant Adenovirus 5 with Adjuvant Oral Tablet Vaccine.
Study NCT04974632 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: localization
Description: small, deep or ground-glass opacity (GGO) lung tumor, Mobile 3D C-arm CT assisted pre-operative localization, video-assisted thoracic surgery(VATS)
Study NCT04334083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison of biomarkers of stress
Description: Emergency will be followed during a night shift and the rest day et during a day shift and the rest day. They will be observed by a medical externship student. We will assess the role of expertise and habituation to stressful emergency situations.
Study NCT05873218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: The intervention will be up to two 7.5 mg doses of ephedrine given after the placement of a combined spinal epidural with 25 mcg intrathecal fentanyl timed 3 and 15 minutes after intrathecal opiate administration.
Study NCT05873218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: Placebo will be administered at matching rate.
Study NCT06247891 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ECS Group
Description: Patients underwent endoscopic and endocytoscopic evaluations.
Study NCT04080895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
Study NCT04080895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Description: Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
Study NCT04080895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine + Amodiaquine
Description: Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2
Study NCT05462509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bCPAP with blenders
Description: The intervention device is a low-cost bCPAP kit which includes two fixed-ratio oxygen blenders that do not require a source of pressurized air. These simple and inexpensive devices sit in-line from the oxygen source and dilute the flowing stream of oxygen with room air, obviating the need for a pressurized source of air. The oxygen may be supplied from either high-pressure sources or low-pressure sources such as oxygen concentrators. Each of the two blenders are single plastic parts, injection moulded from a biocompatible, medical-grade polyethylene resin. No electricity is required for the blenders to provide a stable and constant mix of air and oxygen over the full range of clinically relevant pressure and flows for newborns.
Study NCT05743465 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered in this study.
Study NCT05813509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Organoid culture
Description: Tumor like organ is a kind of organ cultured from tissues of tumor patients, which is a small tumor growing in a culture dish. Compared with the traditional two-dimensional culture system, the most important feature of this technological innovation is that it can directly use the patient's own tissue to culture organ like cells. At the same time, these organ like cells can well replicate some key characteristics of the primary tumor and retain the pathological form and biological mechanism of the patient's tissue
Study NCT05901818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous induced neural stem cell-derived DA precursor cells
Description: The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
Study NCT04812847 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of MDR characteristics
Description: Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
Study NCT05391789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Patients would be given 400000 or 800000units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
Study NCT05391789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
Study NCT05499299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Google ads
Description: Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website
Study NCT05499299 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Google ads
Description: Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website
Study NCT04650867 — intervention group
Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).
Study NCT06123351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denneroll cervical traction orthodontic
Description: traction for 3 to 15 minutes once daily
Study NCT06123351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching and strengthening exercises
Description: strengthening exercises with 10 repetitions twice per day 3 times per week stretching exercises with hold for 20 to 30 seconds 3 repetitions daily
Study NCT06123351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum-formed soft occlusal splint
Description: 2 mm thick elastic rubber sheets
Study NCT06516926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4602
Description: Intravenous infusion, cycle every 21 days;
Study NCT05706051 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: posturography
Description: posturography will be performed when diagnosis of ARHL, in need of hearing aid fitting, is done and after information and written approval from patient. Posturography is performed later when hearing aid fitting and 3months after hearing aid use
Study NCT05532293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSP008-22
Description: MSP008-22 is a small molecule with demonstrated anticancer activity in-vitro \& in vivo studies. As several anticancer drugs are also good antiviral drugs, it was anticipated that MSP008-22 can also be a promising anti-COVID drug. Accordingly, in vitro assay studies and in an in vivo study in golden Syrian hamster were conducted where MSP008-22 has shown good anti-SARSCoV2 effects.MSP008-22.
Study NCT05532293 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical in appearance, taste and smell to the tablets of MSP008-22
Study NCT05113238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assisted gamete activation
Description: compare two different assisted gamete activation protocols to improve ICSI outcome
Study NCT05113238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assisted gamete activation
Description: compare two different assisted gamete activation protocols to improve ICSI outcome
Study NCT05777291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity watch monitoring
Description: Patients will be using activity devices during the study period
Study NCT05777291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep mattress monitoring
Description: Patients will be using sleep mattress during the study period
Study NCT05777291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity counseling
Description: Physical activity counseling in accordance to the Swedish model
Study NCT05777291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: Physical activity counseling in accordance to the Swedish model
Study NCT04948983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision aid (DA) for breast cancer screening
Description: The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?
Study NCT04948983 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standarised information for breast cancer screening
Description: Information provided by the Chilean Ministry of Health in regards to access to breast cancer screening (Age, frequency and costs)
Study NCT05622760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiovisual information
Description: The information provided to this group is in audiovisual format. This information is what has been designed with the aim of reducing the level of anxiety of patients who participate in cervical cancer screening.
Study NCT05622760 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Written information
Description: The information provided to this group is in written format. This information is what is distributed to patients in the midwife's consultation and is available on the website of the health organization (Osakidetza)